A systematic review and meta-analysis on the therapeutic equivalence of statins.
about
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implicationsPitavastatin in cardiometabolic disease: therapeutic profileFamilial hypercholesterolemia: present and future managementStatins in cardiometabolic disease: what makes pitavastatin different?Overview of guidelines for the management of dyslipidemia: EU perspectivesClinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes RegisterStatin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting systemLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.The association between statin medication and progression after surgery for localized renal cell carcinoma.Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.Prescribing efficiency of proton pump inhibitors in China: influence and future directionsStatin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potencySequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events.Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growthDo newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population.Which interventions offer best value for money in primary prevention of cardiovascular disease?Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia.Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic SubjectsNutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.The effects of simvastatin on the serum concentrations of thyroid stimulating hormone and free thyroxine in hypothyroid patients treated with levothyroxine.Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.The current management of carotid atherosclerotic disease: who, when and how?Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.Statin use and clinical osteoarthritis in the general population: a longitudinal study.Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyPotential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savingsImpact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease.Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention: A meta-analysis.Statin prescribing for people with severe mental illnesses: a staggered cohort study of 'real-world' impacts.Targeting tumor cell metabolism with statins.Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
P2860
Q21129272-F1B6F5EC-5253-4BDE-A6D2-F94EA4507F14Q21246037-9269360E-35F2-4BB4-B87F-95F40910E880Q26828489-C02DC0CA-2C9D-418B-89DE-420FB404E3A4Q27010638-94052FD4-ECCB-4C1A-98CC-34E618CB520EQ28069411-499F32D2-3D15-458D-8EEF-04BEE4EB41EAQ28477948-55C835E8-84E4-4610-8D11-7A1F3649BA6FQ28478481-7500993B-05A0-4F76-A968-22041D2BA8DCQ30248925-60D4C395-C4F9-4F4A-ADFA-4274DF9C8A89Q34206127-701FC4B9-A302-4A3A-9B6A-74B55676673CQ34289448-D1F785A2-84A9-45F9-AE05-275431C4EC2FQ34429685-790F6D94-1671-4992-BAC2-A8F7B021DC19Q34456192-C783B555-6FC2-4A3A-95E9-D78FBFD136CCQ35021173-3513B4AB-5BA8-48E7-B335-0E62B89122A4Q35043492-CE55B8E8-1669-484E-91BC-0927B13FA45FQ35116507-D5DE40D2-7553-4C3E-8746-C67E1720FBF5Q35157097-979CEB8E-5C45-415A-BDC2-434684B63D7CQ35625968-0FB116CD-24BD-483F-9426-C891C4EA8E68Q35753875-F1AB94F1-A44F-41FA-9668-28227D8C50D6Q35861885-6E9AEA16-4FA5-4FC5-BEA0-AAD7816F9E60Q35990559-CC8C7725-12C7-4709-9941-83E1E078C982Q36102162-F1C8FC64-6C82-42CF-9EBC-5888F1728090Q36109666-EE7D1320-CB0D-4250-BD05-3806806D0C14Q36139098-44719606-F895-43BD-A3CD-D92EFDFC41D7Q36271369-5C54CC31-B75E-48EF-B873-4D380FC34DD6Q36335047-40E1199C-8D65-41D9-9910-1C7D6B8E2564Q36567072-A252D548-827C-485A-911D-781A2C0AD0F2Q36585817-ABA1B9DB-2423-49A0-8153-ABEC1CD0C10CQ36599659-BD2B74AB-F836-4F90-8A31-733C3D120B27Q36820247-9BEDA40C-5451-4892-9BAC-A30E831436E4Q36927430-20D9EAC5-1536-410E-B492-818BEF3BD67DQ37111887-C3F03A39-53FC-46EA-A746-5084B620521CQ37115301-DEBC8E1A-68B4-40CE-BCC7-189D54A98E9EQ37174306-7A7DAC91-20D2-4807-8105-C236643EDFD3Q37314521-51E9DC9B-C76C-41C2-B620-19ACCCEB12E6Q37473382-548016C6-DA9C-40F9-A66A-89A6A3BC2ABEQ37605860-E2978DB5-07FC-4CD9-834C-4E61A62C9C2FQ37704226-B46A4122-DB71-432E-A398-CE408956F9DBQ37981833-49447760-8175-4558-9312-0F348ACB3F67Q37982202-14813181-4EA2-4F3B-A0BB-9075D2496259Q38080920-FB1F8BE2-2CA6-40A2-A989-48FF1DBF9843
P2860
A systematic review and meta-analysis on the therapeutic equivalence of statins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@en
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@nl
type
label
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@en
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@nl
prefLabel
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@en
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@nl
P2093
P2860
P1476
A systematic review and meta-analysis on the therapeutic equivalence of statins.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2710.2009.01085.X
P577
2010-04-01T00:00:00Z